IUSTI Europe position statement on use of DoxyPEP: June 2024.
| Autor: | Sherrard J; Department of Sexual Health, Buckinghamshire Healthcare NHS Trust, Amersham, UK., Gokengin D; Infectious Diseases, Ege University, Izmir, Turkey., Winter A; Sandyford Sexual Health Services, NHS Greater Glasgow & Clyde, Glasgow, UK., Marks M; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.; Hospital for Tropical Diseases, London, UK., Unemo M; Department of Laboratory Medicine, Microbiology, WHO Collaborating Centre for Gonorrhoea and Other STIs, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.; Institute for Global Health, University College London (UCL), London, UK., Jensen JS; Mycoplasma Laboratory, Statens Serum Institut, Copenhagen, Denmark., Cusini M; STI Centre, Ospedale Maggiore Policlinico, Milano, Italy., Mårdh O; HIV/AIDS, STI and Hepatitis Programme, European Centre for Disease Prevention and Control, Stockholm, Sweden. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of STD & AIDS [Int J STD AIDS] 2024 Nov; Vol. 35 (13), pp. 1087-1089. Date of Electronic Publication: 2024 Aug 21. |
| DOI: | 10.1177/09564624241273801 |
| Abstrakt: | This position statement is aimed at front-line clinical practitioners and public health authorities in WHO European Region providing services for people wishing to reduce their risk of acquiring sexually transmitted infections (STIs), including HIV. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|